
Velpanat Velpatasvir Tablets
Product Details:
Brand |
Velpanat Natco |
Composition |
Velpatasvir 100mg Sofosbuvir 400mg |
Dosage Form |
Tablet |
Dose/Strength |
Velpatasvir 100mg sofosbuvir400mg |
Indications |
Hepatitis C |
Packaging Size |
28 tablets |
Packaging Type |
Bottle |
Uses |
One Tablet OD |
Sofosbuvir-velpatasvir is the first available pangenotypic NS5A-NS5B inhibitor single-pill combination regimen, and is highly efficacious across HCV genotypes 1 to 6. It provides a much-needed interferon-free option for patients with genotype 3 infection that is more economical than sofosbuvir plus daclatasvir, and in patients who have compensated cirrhosis with genotype 3, this single-pill option provides an important ribavirin-free combination. Notably, unlike ledipasvir-sofosbuvir, an abbreviated duration of 8 weeks has not been studied with sofosbuvir-velpatasvir for any of the genotypes, except in conjunction with a third agent (voxilaprevir). Sofosbuvir-velpatasvir, like ledipasvir-sofosbuvir, will be susceptible to drug interactions with acid-reducing agents particularly proton-pump inhibitors and the impact of these agents on real-world clinical effectiveness remains to be determined.
![]() |
SURETY HEALTHCARE
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |